Omalizumab shows efficacy in asthmatics in the long run: claims study

In the analysis, for omalizumab therapy, a total of 989 severe allergic asthma individuals were referred, of whom 854 patients were considered eligible for treatment. Omalizumab therapy was found to be very effective, with this effectiveness sustained after 4 years of treatment. It was shown that at week 16, the success of the therapy can be predicted from the baseline FEV1% and clinical improvement (based on ACQ-7 and miniAQLQ scores).

A detailed analysis of the data brought forth the following facts.

• At weeks 16 and 52, omalizumab was successful in 84% and 91% of patients, respectively.
• Treatment effectiveness was maintained up to the 4-year follow-up.
• Four predictors of the response to omalizumab were found at week 16 and two at week 52.
• The results at week 16 may be used as predictors of success at week 52 based on the model including baseline FEV1% and change in ACQ-7 and miniAQLQ score at week 16: the area under the ROC curve equals 0.746 [95% CI: 0.672– 0.820].

" With an increasing number of available target therapies, predefined criteria for selection of the most suitable treatment for individual patients are needed. In our opinion, it should be based on simple parameters that are easily available for physicians. A predictive model of the long-term response to omalizumab treatment, might include baseline FEV1%, improvement in ACQ-7 and miniAQLQ scores at treatment week 16."wrote the team.

For full article follow the link: https://doi.org/10.2147/JAA.S282203

Primary source: Journal of Asthma and Allergy